PHARMACEUTICALS
Untitled Page
Tustin’s Peregrine presents promising antiviral data
The company participated in the 2009 Chemical and Biological Defense Science & Technology Conference.
By Susan BelknappPublished: November 18, 2009 02:20 PM
Tustin-based Peregrine Pharmaceuticals Inc. announced Tuesday its researchers presented positive data on the study’s progress for the first time on Monday at the 2009 Chemical and Biological Defense Science & Technology Conference in Dallas.
The company is working on a major biodefense initiative funded by the Defense Threat Reduction Agency for the Transformational Medical Technologies Initiative (TMTI), Peregrine Pharmaceuticals was awarded a government contract worth up to $44.4 million to assess the company’s PS-targeting antibodies as broad spectrum agents for the treatment of viral hemorrhagic fevers, a potential biodefense threat.
The presentation was specific to Peregrine’s federally funded preclinical viral hemorrhagic fever (VHF) program, confirming that its phosphatidylserine (PS)-targeting antibodies bind to VHF viruses and virally infected cells and increase survival in a model of lethal VHF infection.
Peregrine’s multi-year program is designed to assess the PS-targeting antibodies as broad-spectrum agents for the treatment of viral hemorrhagic fevers – a potential biodefense threat. The studies evaluated the activity of Peregrine’s PS-targeting antibodies against representatives of major VHF virus families.
NEXT PAGE >>
Related headlines
Orange County Superior Court certifies Abbott suit
Orange Coast Memorial opens CyberKnife, Radiation Oncology Center
Spectrum Pharmaceuticals moves forward with bladder cancer drug
UC Irvine sees success with embryonic stem cell therapy
'OC METRO Minute,' Nov. 10: CHOC Children's plans to lay off 42
|
||||
|
Tustin-based Peregrine Pharmaceuticals Inc. announced Tuesday its researchers presented positive data on the study’s progress for the first time on Monday at the 2009 Chemical and Biological Defense Science & Technology Conference in Dallas. The company is working on a major biodefense initiative funded by the Defense Threat Reduction Agency for the Transformational Medical Technologies Initiative (TMTI), Peregrine Pharmaceuticals was awarded a government contract worth up to $44.4 million to assess the company’s PS-targeting antibodies as broad spectrum agents for the treatment of viral hemorrhagic fevers, a potential biodefense threat. The presentation was specific to Peregrine’s federally funded preclinical viral hemorrhagic fever (VHF) program, confirming that its phosphatidylserine (PS)-targeting antibodies bind to VHF viruses and virally infected cells and increase survival in a model of lethal VHF infection. Peregrine’s multi-year program is designed to assess the PS-targeting antibodies as broad-spectrum agents for the treatment of viral hemorrhagic fevers – a potential biodefense threat. The studies evaluated the activity of Peregrine’s PS-targeting antibodies against representatives of major VHF virus families. NEXT PAGE >> Related headlines Orange County Superior Court certifies Abbott suit Orange Coast Memorial opens CyberKnife, Radiation Oncology Center Spectrum Pharmaceuticals moves forward with bladder cancer drug UC Irvine sees success with embryonic stem cell therapy 'OC METRO Minute,' Nov. 10: CHOC Children's plans to lay off 42 |
||||
